Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957829 | 0.96 | AXL (0.42) | RIPK1KDM1AMAOAAXLTYRO3 | |
| SCHEMBL22957665 | 0.88 | RIPK1 (0.37) | RIPK1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22957682 | 0.85 | RIPK1 (0.42) | RIPK1KDM1AMAOAAXLTYRO3 | |
| SCHEMBL22957908 | 0.84 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22957904 | 0.82 | RIPK1 (0.47) | RIPK1KDM1AMAOAAXLTYRO3 | |
| SCHEMBL22957681 | 0.82 | RIPK1 (0.42) | RIPK1KDM1AMAOAAXLTYRO3 | |
| SCHEMBL22957663 | 0.82 | AXL (0.43) | RIPK1KDM1AMAOAAXLTYRO3 | |
| SCHEMBL22957830 | 0.82 | AXL (0.46) | RIPK1KDM1AMAOAAXLTYRO3 | |
| SCHEMBL24180135 | 0.82 | RIPK1 (0.42) | RIPK1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22957809 | 0.80 | RIPK1 (0.42) | RIPK1KDM1AMAOAAXLTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | RIPK1 1/4885PDE4A 1098/4885PDE4B 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.